Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00743119 · ClinicalTrials.gov registry record · Phase 2

Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers

A Phase 2 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
34
Enrollment target

NCT00743119 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 34 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00743119, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

The following study is designed to determine the analgesic efficacy of smoked marijuana (0, 1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for clinical use of analgesics. Oral THC (dronabinol) is known to have a slower onset and longer duration of action compared with smoked marijuana. Therefore, the analgesic effects of oral THC is expected to peak later and last longer than effects produced by smoked marijuana.

Interventions

  • DRUG Placebo capsules
  • DRUG Inactive marijuana (0% THC)
  • DRUG Low dose Dronabinol
  • DRUG High dose Dronabinol
  • DRUG Low THC marijuana

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2008-06
Est. Completion 2013-05
Phase Phase 2

What the Registry Record Tells You About NCT00743119

The ClinicalTrials.gov registry entry for NCT00743119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Placebo capsules is the first listed.

NCT00743119 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00743119 about?

NCT00743119 is a clinical study titled "Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers". The following study is designed to determine the analgesic efficacy of smoked marijuana (0, 1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for clinical use of analgesics. Oral THC (dronabinol) is known to ...

What is the current status of trial NCT00743119?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2008-06. Estimated completion is 2013-05.

What interventions are being tested in trial NCT00743119?

The interventions under investigation include: Placebo capsules (DRUG), Inactive marijuana (0% THC) (DRUG), Low dose Dronabinol (DRUG), High dose Dronabinol (DRUG), Low THC marijuana (DRUG).

Who is sponsoring clinical trial NCT00743119?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.